MNKD
MannKindANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
MannKind has a confirmed Afrezza pediatric label expansion, a near-term Furoscix ReadyFlow regulatory decision, Q1 2026 revenue of $90.2 million, and developing pulmonary programs that could diversify its commercial base. [#8-K-2026-06-02] [#SEC-8K-2026-05-06]
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Afrezza pediatric approval may not translate into meaningful commercial adoption.
Momentum
66
Value
61
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.45 · Bull $5.25 · Bear $3.15
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.59
Why
Momentum66 · Δ7d -17.4
Value61 · Δ7d -0.1
Sentiment54 · Δ7d -2.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
66
26% active weight
Current posture
7d trendSoftening
Δ7d
-17.4
Δ21d
-24.0
Value
61
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.1
Sentiment
54
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.9
Δ21d
+7.6
Why this grade
Composite grade A. Momentum 66.5 / Value 61.3 / Sentiment 53.7
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.25B
Beta
0.84
Shares Out
308.95M
P/E (TTM)
60.7
P/S (TTM)
5.50
P/FCF (TTM)
39.77
Rev YoY
+15.1%
EPS YoY
-231.5%
Gross Margin
+73.3%
Op Margin
+18.8%
Net Debt
$302.04M
Current Ratio
1.87
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology